Evaluation of Epithelial Lining Fluid Concentration of Amikacin in Critically Ill Patients With Ventilator-Associated Pneumonia
- 22 February 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Intensive Care Medicine
- Vol. 35 (4) , 400-404
Abstract
Introduction: Classically, aminoglycosides are known to have low penetration into the lung tissue. So far, no study has been conducted on human adult patients to evaluate amikacin concentration in epithelial lining fluid (ELF) of the alveoli. Therefore, convincing data are not available from the perspective of pharmacokinetics to support the fact that a dosage of 20 mg/kg of amikacin is sufficient to treat patients with ventilator-associated pneumonia (VAP). Method: This was a pilot study of amikacin concentration measurement in the alveolar site of action in critically ill adult patients with VAP who required aminoglycoside therapy. A dose of 20 mg/kg of amikacin was administered over a 30-minute infusion. The serum concentrations of amikacin were evaluated in the first, second, fourth, and sixth hours. However, the ELF concentration of amikacin was evaluated in the second hour with the help of bronchoalveolar lavage sampling technique. Results: A total number of 8 patients was included in the study. The mean (SD) administered dose was 20 (0.9) mg/kg. The mean (SD) peak plasma concentration of amikacin was 59.6 (23) mg/L, with the volume of distribution of 0.36 (0.13)L/kg. The amikacin concentration in ELF was successfully measured in 7 patients (6.3) mg/L. The lung tissue penetration of the drug was described as alveolar percentage, proportional to both the first- and second-hour plasma concentrations, with a mean (SD) of 10.1% (8.4%) and 18% (16.7%), respectively. Conclusion: To our knowledge, the current study is the first that investigates whether standard doses of amikacin may lead to sufficient alveolar concentration of the drug. The results show that administration of amikacin in doses of 20 mg/kg in critically ill patients with VAP may not provide sufficient concentrations in ELF.Keywords
This publication has 16 references indexed in Scilit:
- Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining FluidClinical Pharmacokinetics, 2011
- Quantification of Amikacin in Bronchial Epithelial Lining Fluid in NeonatesAntimicrobial Agents and Chemotherapy, 2011
- Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining FluidAntimicrobial Agents and Chemotherapy, 2008
- Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patientsIntensive Care Medicine, 2007
- Penetration of Gentamicin Into the Alveolar Lining Fluid of Critically Ill Patients With Ventilator-Associated PneumoniaChest, 2005
- The Prevalence of Nosocomial Infection in Intensive Care Units in EuropeJAMA, 1995
- Antibiotic penetration into lung tissues.Thorax, 1994
- Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patientsAntimicrobial Agents and Chemotherapy, 1993
- Penetration of Netilmicin in the Lower Respiratory Tract after Once-Daily DosingChest, 1992
- Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumoniaThe American Journal of Medicine, 1984